Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403039 · ClinicalTrials.gov registry record · Phase 1
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
A Phase 1 study, sponsored by Vitreous -Retina- Macula Consultants of New York.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00403039 is a Phase 1 study that has completed, run by Vitreous -Retina- Macula Consultants of New York. The registered enrollment target is 41 participants.
The verdict
NCT00403039, a Phase 1 study, has completed, sponsored by Vitreous -Retina- Macula Consultants of New York.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
Interventions
- DRUG Ranibizumab (Lucentis )
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00403039
The ClinicalTrials.gov registry entry for NCT00403039 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vitreous -Retina- Macula Consultants of New York, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab (Lucentis ) is the first listed.
NCT00403039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00403039 about?
NCT00403039 is a clinical study titled "Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema". The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
What is the current status of trial NCT00403039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2006-11. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00403039?
The interventions under investigation include: Ranibizumab (Lucentis ) (DRUG).
Who is sponsoring clinical trial NCT00403039?
This trial is sponsored by Vitreous -Retina- Macula Consultants of New York, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.